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Oncogenic processResistance to apoptosis is an important component of the overall mechanism which drives the tumorigenic
process. EBV is a ubiquitous human gamma-herpesvirus which preferentially establishes latent infection in
viral infected B-lymphocytes. EBNA1 is typically expressed in most forms of EBV-positive malignancies and is
important for replication of the latent episome in concert with replication of the host cells. Here, we
investigate the effects of EBNA1 on survivin up-regulation in EBV-infected human B-lymphoma cells. We
present evidence which demonstrates that EBNA1 forms a complex with Sp1 or Sp1-like proteins bound to
their cis-element at the survivin promoter. This enhances the activity of the complex and up-regulates
survivin. Knockdown of survivin and EBNA1 showed enhanced apoptosis in infected cells and thus supports a
role for EBNA1 in suppressing apoptosis in EBV-infected cells. Here, we suggest that EBV encoded EBNA1 can
contribute to the oncogenic process by up-regulating the apoptosis suppressor protein, survivin in EBV-
associated B-lymphoma cells.rtson).
l rights reserved.© 2010 Elsevier Inc. All rights reserved.Introduction
EBV is a human gamma-herpesvirus known to establish latent
infections in multiple cell types and is associated with a large number
of malignancies, including Burkitt's lymphoma (BL), nasopharyngeal
carcinoma (NPC), Hodgkin's disease (HD), and posttransplant
lymphoproliferative disease (PTLD) (Young and Rickinson, 2004).
Some EBV-positive tumors express only a limited number of latency
proteins, leading to restricted forms of latency in which Epstein–Barr
Virus nuclear antigen 1 (EBNA1) is detected either alone (Latency I,
found in BL) or together with the LMPs (Latency II, found in HD and
NPC, and Latency Ш, found in PTLDs and LCLs) (Leight and Sugden,
2000; Rickinson and Kieff, 2001). Thus, EBNA1 is detected in all types
of malignancies positive for EBV. Moreover, EBNA1 is required for
maintenance of the EBV episome (Hung et al., 2001). This ﬁnding is
consistent with a central role for EBNA1 in maintenance and
segregation of the latent EBV genome (Imai et al., 1998; Rickinson
and Kieff, 1996). EBNA1 also promotes genomic instability via
induction of reactive oxygen species (Gruhne et al., 2009) and in
complex with EBNA1-binding protein 2 (EBP2) can interact with
mitotic chromosomes (Nayyar et al., 2009).As a DNA-binding phosphoprotein, EBNA1 binds to the origin of
viral replication, oriP, critical for latent viral replication and for
tethering of the viral episome to host chromosomes (Marechal et al.,
1999; Yates et al., 1996). Recently, Frappier L. et al. reported that
EBNA1 mediated recruitment of a histone H2B deubiquitylating
complex to OriP, the latent origin of DNA replication (Sarkari et al.,
2009). EBNA1 also interactswith the Bromodomain containing Protein
4 (Brd4) in both yeast and human cells throughN-terminal sequences.
This induces transcriptional activation but not segregation (Lin et al.,
2008). Furthermore, EBNA1 participates in regulation of latent gene
transcription as EBNA1 can bind to a site downstream of the BamHI Q
promoter (Qp) to repress Qp activity (Sung et al., 1994). EBNA1 has
also been shown to up-regulate two key EBV latency promoters, the
BamHI C promoter (Cp) (Sugden and Warren, 1989) and the LMP1
promoter (Gahn and Sugden, 1995). Furthermore, EBNA1 enhances
the activity of the AP-1 transcription factor in NPC (O'Neil et al., 2008),
and is capable of transactivating theWp/Cp promoters responsible for
initiation of transcription of the six EBNAs in type III latency (Imai et al.,
1998; Rickinson andKieff, 1996). EBNA1 can also regulate cellular gene
expression (Canaan et al., 2009) and inhibits the canonical NF-κB
pathway by inhibiting IKK phosphorylation, implicating EBNA1 in the
pathogenesis of NPC (Valentine et al., 2010). Moreover, expression of
EBNA1 in gastric carcinomas cells is associated with enhanced
tumorigenicity (Cheng et al., 2010). In addition, a number of published
studies are consistent with a role for EBNA1 in proliferation of
Fig. 1. Genes up-regulated in BJAB cells expressing EBNA1 by using gene array analysis.
(A) Immunoﬂuorescence assay for EBNA1 in BJAB cells. (B) The genes shown were up-
regulated greater than 2.2-fold in BJAB cells expressing EBNA1. Data was standardized
from BJAB-EBNA1 and BJAB-vector sets by using GEArray Expression Analysis Suite.
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EBV-positive Burkitt's lymphoma cells, by overexpression of a
dominant-negative EBNA1 mutant resulted in increased cell death
(Kennedy et al., 2003). Similarly, down-regulation of EBNA1 in Raji, a
Burkitt's lymphoma cell line or EBV-positive epithelial cells by RNA
interference decreased cell proliferation (Hong et al., 2006; Yin and
Flemington, 2006). Our previous work have also shown that
expression of EBNA1 in breast carcinoma cells promoted the rate of
tumor growth in nude mice, reversed the growth inhibitory effect of
the cellular Nm23-H1 protein and increased lung metastases (Kaul et
al., 2007).
Survivin is an inhibitor of apoptosis expressed in many human
cancer cells but not in normal adult tissues (Altieri, 2008; Hong et al.,
2006). Overexpression of survivin in various cellular systems was
associated with inhibition of cell death (Altieri, 2008). However,
regulation of the survivin gene is complex, involving multiple
pathways regulated by transcriptional and post-transcriptional
strategies (Altieri, 2008). Survivin transcription increases during G1,
and reaches a peak in G2-M (Kobayashi et al., 1999; Li and Altieri,
1999). Survivin has generated considerable interest as a cancer gene,
although no mutations or polymorphisms have been identiﬁed that
selectively induce survivin. Notably p53, or expression of oncogenes
like Ras, results in aberrant survivin promoter activity (Altieri, 2003).
Furthermore, the feasibility of utilizing the survivin promoter to
obtain cancer-speciﬁc expression of therapeutic genes was exploited
in a number of studies (Chen et al., 2004; Chun et al., 2007; Yang et al.,
2004). In addition, survivin is regulated by the developmental
signaling pathway as a direct transcriptional target of Wnt/β-catenin,
which recognizes the discrete T-cell factor (TCF-4)-binding elements
in the survivin promoter (Fodde and Brabletz, 2007). Recent studies
have also shown that survivin is a direct transcriptional target of
Notch-dependent gene expression which involves regulation of the
RPB-Jк-binding sites in the survivin promoter (Lee et al., 2008).
Additionally, the transcription factor GATA-1 is overexpressed in
breast carcinomas and contributes to survivin up-regulation via
promoter polymorphism (Boidot et al., 2010). Recently up-regulation
of survivin expression was due to expression of latent membrane
protein 2A (LMP2A) in EBV-associated gastric carcinoma (Hino et al.,
2008). However, the mechanism of this activation is yet to be fully
elucidated.
Here, we investigated the effects of EBNA1 on survivin expression
in EBV-infected B-lymphoma cells. We present evidence to suggest
that EBNA1 forms a complex with Sp1 or Sp1-like proteins bound to
their cis-element on the survivin promoter. This enhances the activity
of these complexes and up-regulates survivin expression. Survivin
up-regulation was therefore due to EBNA1 expression; and an
increase in apoptosis due to knockdown of EBNA1 or survivin
suggests that EBNA1 plays an important role in cell survival and
proliferation. These results demonstrate that EBNA1 can contribute to
the oncogenic process through inhibition of apoptosis in EBV-positive
B-lymphoma cells.
Results
Survivin is up-regulated in BJAB cells expressing EBNA1
EBNA1 contributes to the replication of the EBV genome and is
essential for persistence of the viral genome in host cells (Kapoor et
al., 2005; Wu et al., 2000). In addition, EBNA1 has been reported to
regulate cellular pathways through its activation as a transcription
factor (Wood et al., 2007). In order to further determine the effects of
EBNA1 on genes associated with a number of these cellular processes,
we utilized a cell cycle speciﬁc array to determine the difference in
mRNA levels with EBNA1 expression when compared to the control
vector alone. Cells expressing EBNA1 showedmodulation in the signal
intensities of a large number of cellular genes. Similarly, spots ofartiﬁcial biotinylated sequence used as controls showed similar levels of
hybridization and conﬁrmed that the biotin labeling was equally
efﬁcient in both BJAB-EBNA1 and BJAB-vector cDNA (data not shown).
Gene array data acquisition and quantiﬁcation of spot intensities in the
membranewere performed by using GEArray Expression Analysis Suite
2.0. Only genes with changes greater than 2.2-fold were considered to
be differentially expressed. These included BIRC5 (baculoviral IAP
repeat-containing 5, or survivin), CCND3 (Cyclin D3), CDC20 (Cell
division cycle 20 homolog, S. cerevisiae), CDKN1A (Cyclin-dependent
kinase inhibitor 1A), CKS2 (CDC28 protein kinase regulatory subunit 2),
CUL1 (Cullin 1), E2F1 (E2F transcription factor 1), KPNA2 (Karyopherin
alpha2),MAD2L2(MAD2mitotic arrest deﬁcient-like2),MCM2(MCM2
minichromosome maintenance deﬁcient 2, mitotin, S. cerevisiae), and
UBE1 (Ubiquitin-activating enzyme E1) (Fig. 1B). The baculoviral
IAP repeat-containing 5 (BIRC5), or survivin, was up-regulated about
3.3-fold above the cut-off (Fig. 1B). Interestingly, survivin belongs to the
inhibitor of apoptosis protein (IAP) family and functions to inhibit
caspase activity and therefore negatively regulates apoptosis (Tamm et
al., 1998). We therefore chose to investigate the levels of survivin
expressed in EBV-infected cells compared to control cells and explored
the potential link between EBNA1 and survivin in EBV-associated
B-lymphoma Cells.
The transcription and protein levels of survivin are induced by EBNA1
The mRNA and protein levels were analyzed and the results
further supported the gene array data showing that survivin
expression was up-regulated. We performed RT-PCR and Western
blot analyses to show the effect of EBNA1 on the levels of mRNA and
Fig. 2. The transcription and protein levels of survivin were induced by EBNA1.
(A, B) Quantitation of survivin transcripts was measured by semi-quantitative RT-PCR.
Total RNA was isolated from 20 million of EBV non-infected BL41 and infected
BL41/B958 cells or BJAB, EBNA1-expressing BJAB cell by using TRIzol reagent. A total of
2 μg of RNA was used to synthesize cDNA. Real-time PCR was performed by using the
Power SYBR green PCR master mix with GAPDH as control. Error bars show standard
deviations; (C) Western blot analysis of endogenous survivin in the EBV-infected BL41
and BJAB cells expressing EBNA1. GAPDH was used for internal control.
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EBNA1 and vector only as control for RT-PCR. The analyses showed
that EBNA1 enhanced the survivin transcript levels to 3.5-fold and
4.2-fold in two Burkitt's lymphoma lines BL41 and BJAB, respectively
(Figs. 2A and B). These results were also consistent with the gene
array data. Furthermore, the effect of EBNA1 on the protein level of
survivin was analyzed byWestern blot. Similarly, survivin levels were
also dramatically up-regulated when EBNA1 was expressed (Fig. 2C).
These results support the contribution of EBNA1 to up-regulation of
survivin.Fig. 3. EBNA1 activated the survivin promoter in a dose-dependent manner. A ﬁxed amount (
5, 10, 15 and 20 μg [numbers 1 to 6]) into 10 million (A) DG75 cells and (B) 293 cells, indiv
luciferase assay. The promoter activity was presented as the fold activation relative to
approximately 3 to 6-fold compared to that of the vector control in DG75 cells as well as in
independent experiments were shown. Western blots showed the expression of myc-tagge
antibody to show equal protein loading.EBNA1 up-regulates the survivin promoter activity in a dose-dependent
manner
Since EBV-infected and EBNA1 expressing cells showed higher
levels of survivin mRNA and protein levels, we further explored the
molecular mechanism of survivin promoter up-regulation by EBNA1.
To analyze the role of EBNA1 on regulating the survivin promoter, we
cloned the full-length promoter into pGL3B vector (Lu et al., 2009). A
ﬁxed amount of full-length survivin promoter-driving luciferase was
cotransfected with increasing doses of pA3M-EBNA1 and total DNA
amount was normalized by the pA3M vector into DG75 and 293 cells.
After 24 h, the cells were harvested for luciferase reporter assays. The
reporter assays showed that EBNA1 can indeed activate the survivin
promoter by approximately 3- to 6-fold compared to that of the vector
alone in DG75 cells as well as in 293 cells in a dose-dependent fashion
(Figs. 3A and B). These results suggest that EBNA1 can up-regulate
survivin expression through regulation of cis-acting elements in the
promoter.
Cis-acting elements within the survivin promoter are important for
EBNA mediated induction of survivin expression
To further conﬁrm that survivin promoter activation is due to
EBNA1 expression, we deﬁned the cis-elements responsible for the
activation of survivin transcription by EBNA1 through 5′-deletion
mutants of the survivin promoter generated by restriction-enzyme
digestion cloned upstream of a luciferase reporter. These constructs
were transfected into HEK 293 cells in the presence or absence of
EBNA1 expression vector. Luciferase activity was measured and
representative results are shown in Fig. 4.
The results showed that a deletion of the NK2 transcription factor
related, locus 5 (Nkx2.5), a cardiac homeobox transcription factor, at
the 5′-end of the survivin promoter (SurPΔNkx) resulted in a more
dramatic effect on survivin promoter activity with EBNA1 of
approximately 9-fold compared to the full-length survivin promoter
(SurP) of about 2-fold and suggest that this elementmay contribute to
EBNA1 mediated up-regulation. However, when the NKx 2.5 and Sp1
sites were both deleted (SurP−269/+1) the fold change was similar2 μg) of the reporter plasmids was transfected or cotransfected with pA3M-EBNA1 (1, 2,
idually. At 24 h posttransfection, cell lysate of each transfection was harvested for the
the reporter-alone control. Deﬁnitely, EBNA can activate the survivin promoter by
293 cells in dose-dependent manner. The means and standard deviations from three
d EBNA1 in cotransfected cells. The blot was stripped and reprobed with anti-GAPDH
Fig. 4. Cis-acting elements within the survivin promoter are important for EBNA1 mediated induction of survivin expression. (A to D) A ﬁxed amount of the wild type (WT) or
mutation type (MT) of survivin promoter reporter plasmid was transfected or cotransfected into 10 million 293 cells with pA3M-EBNA1 expression vector. At 24 h posttransfection,
cell lysate of each transfectionwas harvested for a luciferase assay.Western blots show the expression of EBNA1 in the cotransfected cells. The deletion of GC/Sp1 box (SurPΔGC/Sp1)
in the survivin promoter resulted in an almost complete loss of promoter activity in the presence of EBNA1. The blot was stripped and reprobed with anti-GAPDH antibody to show
equal protein loading. +, presence;−. absence. (E) Schematic showing the survivin WT and MT promoter used in this study. The putative domains include an NKx 2.5, Sp1 binding
sites, GC/Sp1 domain and p53 conserved sequence. Numbering is from the initiating ATG.
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GC/Sp1 box (SurPΔGC/Sp1) of the survivin promoter resulted in an
almost complete loss of promoter activity (Figs. 4B and E). Further,
mutation of the p53 responsive element (SurPΔp53) had a small
effect on the promoter activity (Figs. 4C and E), whereas deletion of
GC/Sp1 box and the p53 responsive element (SurPΔGC/Sp1+p53)
together resulted in little or no change in promoter activity compared
to SurPΔGC/Sp1 suggesting that it may not be critical for the p53 site
to cooperate with other cis-elements like Sp1 and the GC rich box to
regulate survivin expression (Figs. 4D and E). These results suggested
that GC/Sp1 was the major cis-element within the survivin promoterresponsive to EBNA1 expression as deletion of this region had the
most dramatic effect on survivin expression.
The p53 responsive cis-acting element is not responsive to EBNA1 at the
survivin promoter
To test whether the p53 cis-acting element was responsive to the
EBNA1 expression, similar assays were performed in the p53-null cell
line Saos-2. Importantly, mutation of the p53 responsive element had
no signiﬁcant fold change in activity on the survivin promoter when
compared to the control pGL3B-SurP (Fig. 5, compare lanes 2 and 7).
Fig. 5. Reporter assay of the survivin promoter with GC/Sp1 and p53 mutation in Saos-2
cells. A ﬁxed amount of the WT or MT reporter plasmid was transfected into 10 million
Saos-2 cells in the presence of pA3M-EBNA1 expression vector. At 24 h posttransfection,
cell lysate of each transfectionwas harvested for a luciferase assay. Obviously, mutation of
p53 responsive element had no signiﬁcant effects on the survivin promoter activity
compared to the control pGL3B-SurPwith EBNA1.+, presence;−, absence.Western blots
show the expression of EBNA1 in cotransfected cells. The blot was stripped and reprobed
with anti-GAPDH antibody to show equal protein loading.
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survivin promoter activity compared to the control pGL3B-SurP with
and without EBNA1 expression (Fig. 5, compare lane 2 with lanes 5
and 6). In combination, the mutation of the GC/Sp1 and p53
responsive elements resulted in an almost 100% decrease in survivin
promoter activity as compared to the control pGL3B-SurP with EBNA1
(Fig. 5, compare lanes 2, 5, and 9). These results suggested that the
p53 responsive element in the survivin promoter may not be a major
contributor to up-regulation of survivin by EBNA1.
Sp1 forms a complex with EBNA1 and its canonical binding site at the
survivin promoter
The survivin gene promoter contains a canonical, Sp1 or Sp1-like
element and deletion of these sites results in abrogation of the
promoter activity. Thus, the Sp1 transcription factor is involved in
survivin gene regulation. To test whether EBNA1 mediated up-
regulation of the survivin promoter through formation of a complex
with EBNA1 and Sp1 at its cognate sequence, EMSAs were performed.
The wild-type andmutant probes for EMSAs were designed to contain
Sp1 elements from the survivin promoter and mutations within the
Sp1 site where Sp1 would be incapable of binding.
To determine whether EBNA1 formed a complex with Sp1 bound
to DNA, double-stranded DNA probes for the Sp1 binding site were
labeled and tested for binding to Sp1 protein from the nuclear extracts
of Saos-2 cells expressing Sp1. The result showed that the wild-type
Sp1 probes had a speciﬁc shift with the Sp1 protein from Saos-2 cells
(Fig. 6, lane 2). The speciﬁcity of the shift was veriﬁed by using excess
speciﬁc cold competitor (Fig. 6, lane 3) which abolished the shift. The
use of similar amounts of cold mutant probe was not able to abolish
binding of Sp1 to the speciﬁc probe (Fig. 6, lane 4) and suggests
speciﬁcity of the Sp1 interaction at the survivin promoter. That the
shift was due to Sp1 was conﬁrmed by using an α-Sp1 speciﬁcantibody which supershifted the complex (Fig. 6, lane 5). Further,
addition of EBNA1 to the reaction mixture supershifted the entire
complex suggesting formation of a complex between Sp1 and EBNA1
(Fig. 6, lane 7). Importantly, the use of anti-myc antibody shifted the
complex further conﬁrming the association of the complex of EBNA1,
Sp1 and the cis-acting DNA element (Fig. 6, lane 6). Because Sp1 is an
essential factor in cells, a shift which is most likely due to endogenous
Sp1 is seen in lane 9 (pA3Monly). This is conﬁrmedwhen the cold Sp1
probe is added and the shift disappeared (lane 10). EBNA1 (lane 11)
showed a shift compared to a similar Sp1 shift (lane 2). However,
when cold Sp1 probe was added, the shift in the EBNA1 lane
disappeared suggesting speciﬁcity for endogenous Sp1 (lane 12).
Together, these results strongly implicated that EBNA1 up-regulates
the survivin promoter through formation of a complex with EBNA1
bound to Sp1 at its cognate sequence.
Furthermore, chromatin immunoprecipitation was performed on
EBV-positive LCL1 cells. IPs was conﬁrmed by Western blotting
(Fig. 6C). Cellular chromatin from LCL1 cells were immunoprecipitated
using EBNA1 antibody. Normal mouse IgG was used as a negative
control. Recovery of the survivin promoter template was detected by
real-time PCR using speciﬁc primer amplifying the GC/Sp1 element
within the survivin promoter. As shown in Fig. 6D, normal mouse IgG
did not amplify any template from survivin promoter, but in the anti-
EBNA1 ChIP, similar amounts of survivin promoter sequence were
immunoprecipitatedwith EBNA1 antibody from LCL1 cells compared to
input. This supports our result above which demonstrates a speciﬁc
association of EBNA1 with the survivin promoter (Fig. 6D). This study
further demonstrates that EBNA1 binds to Sp1 canonical binding site.
The EBNA1 transactivation domain is responsible for up-regulating the
survivin promoter
The data above showed that Sp1 can interact with EBNA1. We
therefore decided to determine the domain responsible for up-
regulation of survivin expression. Different EBNA1 truncations were
cotransfected with the luciferase reporter plasmid carrying the
survivin promoter. The promoter activities were monitored by
luciferase activities. The mutant p376 which lacks the Gly-Ala repeats
and mutants p385 and p396, which lack the looping and DNA binding
and a region of the dimerization domain respectively, show a slight
decrease in survivin promoter activity compared to wild-type EBNA1
indicating that those domains are important in contribution to EBNA
activity at the promoter. The p378 mutant which knocks out the small
Gly-Arg repeat region 5′ to the transactivation domain showed a
slight stimulus on survivin promoter indicating that this domain is not
involved in EBNA1 up-regulation of survivin expression. However, the
mutant p367 which truncated the transactivation domain had a
signiﬁcant decrease in its ability to activate the survivin promoter.
Therefore the domain which lies between amino acids 65 and 89 is
critical for EBNA1 mediated up-regulation of survivin expression
(Fig. 7).
Survivin expression is up-regulated in EBV-associated lymphoma tissue
To determine whether the survivin expression is also up-regulated
in EBV-associated cancer tissue, sections of EBV-positive and -negative
DLBL tissue were stained by immunohistochemistry to determine the
presence of EBNA1 and survivin (Fig. 8). Survivin was detected using
mouse monoclonal anti-survivin antibody followed by detection using
anti-mouse Alexa Fluor 488. EBNA1 was detected using rabbit
polyclonal anti-EBNA1 antibody (K67.3) followed by anti-rabbit Alexa
Fluor 594. In the immunostained sections, high expression of survivin
overlapped with the expression of EBNA1 which showed that in
EBV-positive tumor cells survivin expression was also up-regulated.
This was clearly distinct from the lack of observed signals in an
Fig. 6. Sp1 binds to the survivin promoter in complex with EBNA1 at its canonical binding site. Electrophoretic mobility shift assays were performed as described in Materials and
methods. (A) Binding of Sp1 site in the survivin promoter with EBNA1 protein as well as Sp1. Lane 1 is probe alone (bottom), lane 2 is probe with nuclear extract containing Sp1
showing faster mobility of the probe which was abolished by adding an excess (200-fold) of unlabeled speciﬁc probe (lane 3). The shift in mobility was unaffected with similar
amounts (200-fold) of nonspeciﬁc unlabeled competitor (lane 4). Adding anti-Sp1 antibody changed the mobility of Sp1 (lane 5, asterisk). Lane 7 contains probe with nuclear
extracts of pA3M-EBNA1 showing a change in the mobility of the probe due to the binding of Sp1 to EBNA1 (asterisk). Further, adding anti-myc antibody changed the mobility of the
entire complex, supershifting it (lane 6, asterisk). Lane 8, which contains Sp1 andα-myc antibodies with probe, demonstrates that nonspeciﬁc binding did not occur. Lane 9 is vector
control only but contains the cell essential factor Sp1, This is conﬁrmedwhen the cold Sp1 probe is added and the shift disappeared (lane 10). The EBNA1 (lane 11) still has some shift
compared to Sp1 (lane 2), but when cold Sp1 probe is added, EBNA1 does not show obvious shift compared to EBNA1 (lane 12) NE, nuclear extract. (B) Western blots to detect
proteins from nuclear extracts. (C) LCL1 cells were harvested; cross-linked chromatin was precipitated with OT1x antibody or normal mouse IgG. Western blot shows the
coimmunoprecipitation using OT1x antibody against EBNA1. (D) The recovered DNA was quantitated by real-time PCR. Shown are the results from three independent experiments.
Error bars indicate standard deviations.
69J. Lu et al. / Virology 410 (2011) 64–75EBV-negative tumor tissue section suggesting that EBV infection and
EBNA1 expression were important for survivin expression.
Depletion of survivin using shRNA increases the proportion of cells
undergoing apoptosis
The cell cycle phases (G1, S or G2/M phase) are characterized by
their DNA content. Propidium iodide (PI) binds to DNA at a ratio of
1:1, and hence the DNA content of cell cycle phases is a reﬂection of
their PI ﬂuorescent intensities. Cell cycle analysis was performed on a
FACSCalibur cytometer. We hypothesized that EBNA1 can usurp the
apoptotic pathway to regulate cellular apoptosis through regulation of
survivin expression. Transduction and selection of EBV-infected cells
by lentivirus-delivered shRNA resulted in stable cell lines expressing
survivin-speciﬁc shRNA and EBNA1 speciﬁc shRNA as well as a control
shRNA vector. The cells with GFP immunoﬂuorescence were moni-
tored using an Olympus IX71 ﬂuorescent microscope (Fig. 9A). The
expression levels of survivin and EBNA1 in these cells along with
control shRNA were determined by Western blot analysis (Fig. 9B).
The results showed that survivin and EBNA1 expression levels were
knocked down in cells infected with survivin or EBNA1 speciﬁc shRNA
lentivirus (Fig. 9B). Furthermore, analysis of cells for apoptosis
showed that the LCL1 cells infected with the sh-SV lentivirus showed
an increase in cell apoptosis compared to the LCL1 infected sh-C cells
(Fig. 9C). LCL1 cells with a lentivirus-delivered shRNA that speciﬁcallyknocks down EBNA1 expression in these cells (LCL1-sh-E1) led to a
decrease in apoptosis compared to LCL-sh-SV (Fig. 9C) albeit less than
seen directly with sh-SV lentivirus. This was expected as the level of
survivin shutdown was not as efﬁcient compared to when survivin
was directly targeted by sh-SV. The results support a critical role for
survivin in viral infected cells with a direct role in suppression of
apoptosis in the EBV-infected lymphoma cells contributing to the cell
survival.
Discussion
Many tumor viruses play an essential role in both the initiation and
subsequent progression of cancer. Survivin is an inhibitor of the
apoptosis protein expressed in many human cancer cells but not in
most normal adult tissues (Ambrosini et al., 1997). Its expression is
up-regulated by a number of proteins encoded by tumor viruses (Lu et
al., 2009; Pina-Oviedo et al., 2007; Zhang et al., 2005; Zhou and Gong,
2006; Zhu et al., 2003). The E6 protein of human papillomavirus type
16 up-regulates survivin expression through interaction with p53
(Borbely et al., 2006). The survivin promoter was also transactivated
by the T-cell leukemia virus type I Tax protein, via the activation of NF-
κB (Kawakami et al., 2005). Survivin is also up-regulated by the
hepatitis B virus X protein (HBx), forms a complex with HBx-
interacting protein and binds pro-caspase 9, preventing its recruit-
ment by Apaf1 in hepatoma cells (Marusawa et al., 2003). Recently,
Fig. 7. The EBNA1 transactivation domain is required for activation of the survivin
promoter. (A) A ﬁxed amount of the WT or MT EBNA1 expression vector was
transfected into 10 million 293 cells in the presence of survivin promoter reporter
plasmid. At 24 h posttransfection, cell lysate of each transfection was harvested for a
luciferase assay. Results of luciferase assay showed that EBNA1/p367 had a signiﬁcant
decrease in its ability to activate the survivin promoter. All the transfections were done
multiple times, and the results shown represent the means of the data from three
independent experiments. Western blots show the expression of EBNA1 and
truncations in the cotransfected cells. The blot was stripped and reprobed with
anti-GAPDHantibody to showequal protein loading.+,presence;−, absence. (B) Schematic
showing the EBNA1 truncation used in this study.
70 J. Lu et al. / Virology 410 (2011) 64–75the EBV encoded LMP2A protein was shown to up-regulate survivin
expression in EBV-associated gastric carcinoma (Hino et al., 2008).
Therefore up-regulation of survivinmay be a common denominator in
viral mediated oncogenesis. Additionally, EBNA-1 mRNA levels are
up-regulated in S phase (Davenport and Pagano, 1999). Thus EBNA1
may provide (survivin and/or USP7/p53-related) survival effects in
dividing cells countering signals that instruct the cell to stop and
repair damage. Recently, Frappier L. et al. reported that EBNA1 affects
PML bodies and potentially affects DNA repair also supporting the
pro-oncogenic potential of EBNA1 (Sivachandran et al., 2008). This
may be relevant for “general” survival of dividing EBV-positive cells in
normal biology, and contributes to the oncogenic risk in EBV-positive
cells that are challenged or contain damaged DNA.
EBV is a ubiquitous human herpesvirus associated with the
development of both lymphoid and epithelial tumors (Rickinson
and Kieff, 2001). The pattern of EBV latent protein expression in
these tumors is different from that observed in EBV-transformedlymphoblastoid cell lines (LCLs) (Raab-Traub, 2002; Young and
Rickinson, 2004). Thus, only EBNA1 is typically expressed in Burkitt's
lymphoma (BL), while EBNA1 and two membrane proteins (LMP1 and
LMP2A/B) are expressed in Hodgkin's lymphoma (HL) and nasopha-
ryngeal carcinoma (NPC) (Raab-Traub, 2002; Rickinson and Kieff,
2001). However, a more direct involvement in oncogenesis has been
suggested by the ability of B-cell-directed EBNA1 expression to produce
B-cell lymphomas in transgenicmice, although these are still unresolved
questions (Kang et al., 2005; Wilson et al., 1996), as to its possible
contribution to BL cell survival in vitro (Kennedy et al., 2003).
In this report we showed that EBNA1, which is known to be
expressed in all EBV-positive tumors, up-regulated survivin expres-
sion in the EBV-infected B-lymphoma cells. Survivin was shown to be
up-regulated in human cancers showing its antiapoptotic activity and
its ability to regulate cell-cycle progression (Ambrosini et al., 1997).
Importantly, EBNA1 is expressed in all forms of EBV-infected cells and
plays a role in segregation and maintenance of the episomal EBV
genome (Imai et al., 1998; Rickinson and Kieff, 1996, 2001). EBNA1 is
consistently detected in all EBV-associated tumors, including lym-
phoproliferative disease (Hammerschmidt and Sugden, 2004). The
function of EBNA1 has been extensively studied in B cells, where in
vitro infection with EBV is efﬁcient and results in B-cell transforma-
tion (Rickinson and Kieff, 1996; Yates et al., 1985). In addition,
increasing evidence also suggests that EBNA1 may directly contribute
to tumorigenesis by inhibiting apoptosis (Kennedy et al., 2003;
Saridakis et al., 2005). However, its role with regard to survivin in
EBV-infected B-lymphoma cells is yet to be completely elucidated.
The possibility that EBNA1 has additional functional effects beyond
its crucial role in the maintenance and replication of the EBV episome
has been suggested for some time. The ability of EBNA1 to tran-
scriptionally regulate viral genes is well accepted and previous reports
implicated EBNA1 in the control of speciﬁc cellular genes in B cells
(Tsimbouri et al., 2002). Moreover, Wood et al. (2007) reported that
EBNA1 regulates cellular gene transcription andmodulates STAT1 and
TGFβ signaling pathways. Our gene array analysis from BJAB
expressing EBNA1 showed that many cellular factors were up-
regulated in EBNA expressing cells, including one referred to as the
inhibitor of apoptosis protein also called survivin. This suggests that
EBNA1 can activate survivin gene expression. Up-regulation of
survivin expression was due to LMP2A in EBV-associated gastric
carcinoma (Hino et al., 2008). However, EBV-associated lymphoma
cells do not express all the latent proteins, leading to restricted forms
of latency in which EBNA1 is detected alone (Latency I, found in BL).
We further decided to investigate a potential mechanism linked to
development of EBV-associated cancer through an increasing survivin
expression by the major latent protein EBNA1 in the EBV-infected
B-lymphoma.
The expression of survivin was highly induced with the expression
of EBNA1 seen in the immunostained sections which suggested that
EBV-positive cells up-regulated survivin expression in tumor cells.
This indicated that EBNA1, in addition to other latent proteins, may
play an important role in up-regulation of survivin expression in
EBV-associated lymphoma, thus contributing to EBV-associated
tumorigenesis. However, the molecular basis for the observed effects
of EBNA1 on cellular apoptosis is largely unknown, though expression
of EBNA1 in U2OS cells was shown to protect these cells from
apoptosis in response to DNA damage by interfering with p53
stabilization (Saridakis et al., 2005). In a recent study, TE7 cells
showed loss of p53 expression and demonstrated increased tran-
scription of the survivin gene. Overexpression of wild-type human
p53 in TE7 cells decreased transcription of the survivin gene as
determined by the mRNA level (Chang et al., 2010). Here we
conﬁrmed that EBNA1 can form a complex with Sp1 bound to its
responsive element on the survivin promoter and so up-regulate
survivin expression. However, up-regulation of survivin is not likely
due to a complex of EBNA1 and p53 bound to its binding site. These
Fig. 8. Survivin expression is up-regulated in EBV-associated lymphoma tissue. Immunohistochemistry assays for survivin and EBNA1 were performed in EBV-positive and -negative
tissue specimens. Parafﬁn-embedded EBV-positive and -negative diffuse large B-cell lymphoma (DLBL) tissues were deparafﬁnized, rehydrated, and washed with phosphate
buffered saline. Following antigen retrieval, samples were blocked with BSA prior to incubation with primary antibodies overnight at 4 °C. Survivin was detected by using mouse
monoclonal anti-survivin antibody followed by detection using anti-mouse Alexa Fluor 488 (panel A) and EBNA1was detected by using rabbit polyclonal anti-EBNA1 antibody K67.3
followed by anti-rabbit Alexa Fluor 594 (panel B). The Merge panel shows most of the survivin co-expression with EBNA1 (panel D).
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Sp1 and EBNA1 were cotransfected with the reporter plasmid, the
cooperative effects of Sp1 and EBNA1 resulted in an approximately
2-fold increase in Cp activation compared to the effect of Sp1 alone
(Nilsson et al., 2001). Reporter assays using the truncations of EBNA1
protein showed that the EBNA1 transactivation domain is an
important region required for EBNA1 binding to Sp1 with the survivin
promoter resulting in up-regulation of survivin expression. Knock
down of EBNA1 expression in the EBV-associated cells further
supported our hypothesis that EBNA1 can up-regulate survivin,
enhance resistance of cell to apoptosis and so increase cell survival
(Fig. 9D). These ﬁndings strongly suggest a role for EBNA1 in
suppressing of cell apoptosis andmay thus contribute to themultistep
process of tumor development. Here the results suggest that EBV
encoded EBNA1 can support the oncogenic process by up-regulating
the apoptosis suppressor protein survivin in EBV-associatedB-lymphoma
cellswhich leads to tumordevelopment andprovides further insights into
the overall contributions of EBV to human cancer.
Materials and methods
Constructs, cell lines and antibodies
The expression constructs of EBNA1 (pcDNA-EBNA1) used in the
present study have been described earlier (Murakami et al., 2005).
Mutant EBNA1 p367, p376, p378, p385, and p396 were kindly
provided by John Yates (1988).
The EBV-negative cell lines BJAB and DG75 and the EBV-positive
cells LCL1were cultured in an RPMI 1640medium supplementedwith7% fetal bovine serum, 2 mML-glutamine, and penicillin–streptomycin
(5 U/ml and 5 μg/ml, respectively). The human embryonic kidney 293
(HEK293) cell line and p53-null Saos-2 osteosarcoma cells were
cultured in Dulbecco's modiﬁed Eagle's medium (DMEM) supplemen-
ted with 5% fetal bovine serum, 2 mM L-glutamine, and penicillin–
streptomycin (5 U/ml and 5 μg/ml, respectively). BJAB cells stably
expressing EBNA1 were described previously (Kaul et al., 2007).
BL41–B958 cell line is an EBV-infected Burkitt's lymphoma cell line
and has been previously described (Subramanian et al., 2001).
Survivin antibody was purchased from Cell Signaling Technology,
Inc. (Danvers, MA). Rabbit polyclonal antibody K67.3 and mouse
monoclonal antibody OT1x were kindly supplied by Jaap Middeldorp
(Department of Pathology at VU University Medical Center, Amster-
dam, The Netherlands) (Sears et al., 2004). The rabbit serum against
EBNA1 (raised against EBNA1-[452–641]) was kindly supplied by Lori
Frappier (Department of Molecular Genetics at the University of
Toronto, Ontario, Canada) (Holowaty et al., 2003). Antibody for Sp1
transcription factor was purchased from Santa Cruz Biotechnologies
Inc. (Santa Cruz, CA).RNA extraction, gene array hybridization and data analysis
Total RNA was extracted from BJAB expressing EBNA1 or BJAB-
vector cells using TRIzol reagent according to the manufacturer's
instruction (Life Technologies, Gaithersburg, MD). Gene arrays were
performed essentially as described previously (Lu et al., 2009) using
the super array cell-cycle membrane (OHS-020). Data acquisition and
quantiﬁcation of spot intensities were performed by using the
Fig. 9. Depletion of survivin by shRNA increases the proportion of cell undergoing apoptosis. (A) LCL1 cells were infected with a lentivirus encoding survivin shRNA and analyzed by
ﬂuorescencemicroscopy after 48 h for the expression of GFP. (B)Western blotting showing expression of EBNA 1 and survivin in EBV non-infected cell line and EBV-infected cell line.
GAPDH level was used for internal control. (C) Flow cytometry analysis of different treated cells. LCL1 cells were treated with survivin shRNA and then washed, ﬁxed, stained with
propidium iodide (PI), and analyzed for their DNA content by ﬂow cytometry. LCl1 cells infected with the sh-SV lentivirus had an increase in cell apoptosis compared to the
LCL1 infected sh-C cells, LCL1 cells with a lentivirus-delivered shRNA that knocks down EBNA1 expression in these cells (LCL1-sh-E1) led to a decrease in apoptosis compared to
LCL1-sh-SV. sh-SV, survivin shRNA; sh-C, control shRNA; sh-E1, EBNA1 shRNA. (D) Hypothetical model showing that EBV encoded EBNA1 contributes to up-regulation of survivin
and resistance to apoptosis in EBV-associated B-lymphoma cells.
72 J. Lu et al. / Virology 410 (2011) 64–75GEArray Expression Analysis suite software 2.0 (SABiosciences,
Frederick, MD).
Immunoﬂuorescence
Immunoﬂuorescence assayswere performed essentially as described
previously (Lu et al., 2009). Brieﬂy, BJAB-vector and BJAB-EBNA1 stablecells on cover slideswere ﬁxed in 3% paraformaldehydewith 0.1% Triton
X-100 for 20 min. Cover slides were washed with 1× PBS and
subsequently blocked in 1% bovine serum albumin for 10 min. Cells
werewashedwith 1× PBS and EBNA1were detected using rabbit serum
raised against EBNA1 (Holowaty et al., 2003) followedbydetectionusing
anti-rabbit Alexa Fluor 488 (Molecular Probes, Eugene, OR). The slides
were examinedwith a Fluoview FV300 (Olympus,Melville, NY) confocal
73J. Lu et al. / Virology 410 (2011) 64–75microscope and the images were analyzed with FLUOVIEW software
(Olympus, Melville, NY).
Luciferase assay
Luciferase assays were performed as described previously (Lu et al.,
2009). Luminescence was measured for 10 s by the Opticomp I
luminometer (MGM Instruments, Hamden, CT). The lysates were also
tested at various dilutions to ensure that luciferase activity was within
the linear range of the assay. The results shown represent experiments
performed in triplicate.
Real-time quantitative PCR
Total RNAs fromcellswere collectedusing TRIzol reagent (Invitrogen,
Carlsbad, CA) following themanufacturer's instructions. cDNAwasmade
using high capacity RNA-to-cDNA kit (Applied Biosystems, Foster City,
CA) following the manufacturer's instructions. The speciﬁc primers for
survivin are 5′-CAGCCCTTTCTCAAGGACCA-3′ and 5′-TGTTCCTCTATGGG
GTCGTC-3′; for GAPDH (glyceraldehyde-3-phosphate dehydrogenase),
5′-TGCACCACCAACTGCTTAG-3′ and 5′-GATGCAGGGATGATGTTC-3′. The
cDNA was ampliﬁed using Power SYBR green PCR master mix (Applied
Biosystems, Foster City, CA), 1 μM each primer, and 1 μl of the cDNA
product in a total volume of 20 μl. Thirty-ﬁve cycles of PCR (1 cycle
consisting of 1 min at 94 °C, 30 s at 56 °C, and 40 s at 72 °C), followed
by 7 min at 72 °C, were performed in an MJ Research Opticon II
thermocycler (MJ Research, Waltham, MA). Each cycle was followed by
two plate readings, with the ﬁrst at 72 °C and the second at 85 °C. A
melting curve analysis was performed to verify the speciﬁcity of the
products, and the values for the relative quantitation were calculated by
the ΔΔCt method. The experiment was performed in triplicate.
Preparation of nuclear extracts and electrophoretic mobility shift assay
Nuclear extracts were prepared from transiently transfected Soas-2
cells with different expression constructs and an empty vector as
described previously (Verma and Robertson, 2003). Speciﬁc probes
were used for the electrophoretic mobility shift assay (EMSA)
encompassing the GC/Sp1 box (5′-GCACCCCGCGCCGCCCCGCCTC
TACTCCCAG-3′) and mutant GC/Sp1 box (5′-GCACCCGAATTCATG-
GATCCTCTACTCCCAG-3′). The 32P-labeled probes were synthesized
via the Klenow ﬁll-in reaction and puriﬁed with Select-D G-25 columns
(Shelton/IBI, Peosta, IA). Radioactive probes were diluted in TE buffer to
a ﬁnal concentration of 80,000 cpm/μl. DNA-binding reactions were
performed in a manner similar to that described previously (Knight et
al., 2001). Proteins from nuclear extracts were mixed with 1 μg of poly
(dC/dI) (Sigma-Aldrich, St. Louis, MO) in 1× DNA-binding buffer for
5 min at room temperature; 1 μl of labeled probe was added to each
reactionmixture, and the tubeswere incubated at room temperature for
15 min. DNA–protein complexes were resolved in a nondenaturing
6% polyacrylamide gel electrophoresis. The gel was run in 0.5× Tris–
borate–EDTA buffer at a constant voltage of 120 V for 4 h. Following
electrophoresis, the gelwas transferred toWhatmanpaper anddried for
1 h at 80 °C. Dried gels were exposed to a phosphorimager screen for
12 h (Amersham Biosciences, Piscataway, NJ) and scanned by a
PhosphorImager (Molecular Dynamics, Piscataway, NJ). For speciﬁcity
determination, cold competitor probe was added at a 200-fold molar
excess. For supershift experiments, polyclonal antibodies against Sp1
were added after an initial 30-min incubation of probe with nuclear
extract and incubated for 1 h at 4 °C.
Immunohistochemistry
Slides mounted with sections of parafﬁn-embedded, archival,
deidentiﬁed EBV-positive and -negative Diffuse large B-cell lymphoma
(DLBL) tissue specimens were a generous gift from Mariusz A. Wasik(Department of Pathology and Laboratory Medicine, Hospital of the
University of Pennsylvania, Philadelphia, PA). Slides were deparafﬁ-
nized, rehydrated, and washed with PBS. Following antigen retrieval in
0.5%:5 mg/ml pepsin with 0.1 N HCL at 37 °C for 10–15min, samples
were blockedwith 2%ﬁsh stain gelatin prior to incubationwith primary
antibodies overnight at 4 °C. Survivin was detected by using mouse
monoclonal anti-survivin antibody followed by anti-mouse Alexa Fluor
488 (Molecular Probes, Eugene, OR), and EBNA1 was detected by using
Rabbit polyclonal antibody K67.3 followed by anti-rabbit Alexa Fluor
594 (Molecular Probes, Eugene, OR). Fluorescence confocal microscopy
was performed with an Olympus microscope (Olympus, Melville, NY).
Construction of lentiviral vectors
The small hairpin RNAs (shRNA) against EBNA1 (GGAGGTTCCA
ACCCGAAAT) were constructed by annealing two primers containing
the 19-nt sense and reverse complementary targeting sequences
with a 9-nucleotide loop – TCTCTTGAA – and ﬂanking XhoI and MluI
cloning sites and then cloned into pGIPZ (Open Biosystems,
Huntsville, AL) plasmid (EBNA1 shRNA is hereinafter abbreviated as
sh-E1) (Yin and Flemington, 2006). The sequences of the insertions
were conﬁrmed by DNA sequencing. The control shRNA (abbreviated
as sh-C) and survivin shRNA (abbreviated as sh-SV) were described
previously (Lu et al., 2009).
Lentivirus production and establishment of shRNA expressing stable cell
lines
Lentiviruswith shRNA expression cassette was produced by calcium
phosphate-mediated, three-plasmid transfection of 293 T cells as
previously described (Lu et al., 2009). Recombinant lentiviruses were
concentrated by spinning at 23,500 rpm for 2.5 h, then dissolved in
RMPI 1640 (HyClone, Logan, UT) at room temperature for 30 min. Titers
were determined by infecting 293 T cells with serial dilutions of
concentrated lentivirus and counting Turbo GFP positive cells after 48 h
underﬂuorescentmicroscopy. The concentrated viruswasused to infect
105 cells in a six-well plate in the presence of Polybrene (8 mg/ml). After
72 h, themediumwas replacedwith2 mlRPMI 1640 containing2 μg/ml
puromycin. For selection, colonies were expanded and expression
checked by Western blot analysis. The control shRNA were labeled as
sh-C and survivin shRNA expressing cells were labeled as sh-SV.
Flow cytometry and apoptosis assays
These assays were performed essentially as described previously
(Riccardi and Nicoletti, 2006). Brieﬂy, cells were harvested and ﬁxed in
70% ice-cold ethanol and stored at −20 °C for later analysis. The ﬁxed
cellswere collectedby centrifugationat400 gandwashedwith coldPBS–
saline twice. Cells were suspended in propidium iodide (PI) staining
solution (50 μg/ml ﬁnal concentration) supplemented with 200 μg of
RNase A per ml and incubated for 30 min at room temperature and then
overnight at 4 °C in the dark. Cell-cycle distributionwas then analyzed by
ﬂow cytometry with a FACScan instrument (Becton–Dickinson, Franklin
Lakes, NJ). Total populations were gated to remove doublets and small
debris. A total of 20,000 events were analyzed for each sample. Data was
analyzed using the ModFIT model program (Becton–Dickinson, Franklin
Lakes, NJ).
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation (ChIP) was performed as previ-
ously described (Verma et al., 2006, 2007). Brieﬂy, EBV-positive cells
LCL1 were collected and DNA was cross-linked and then sheared by
sonication to an average length of 700 bp, as conﬁrmed by agarose gel
electrophoresis. Quantiﬁcation of recovered DNA was determined
using real-time PCR (StepOnePlus™ Real-Time PCR Systems; Applied
74 J. Lu et al. / Virology 410 (2011) 64–75Biosystems, Foster City, CA) and primers (For GC/sp1 responsive
element, 5′ AAAGCAGTCGAGGGGGCG 3′ and 5′ TTCTGGGAGTAGAGG
CGG 3′) designed with computer software (DNASTAR Lasergene 8,
Madison, WI). The entire experiment was performed in triplicate and
error bars indicate standard deviations.
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